|
BOTH HYPO AND HYPERGLYCEMIC EFFECTS HAVE BEEN REPORTED RARELY ; POSSIBILITY EXISTS THAT DICLOFENAC MAY ALTER PATIENTS RESPONSE TO ORAL HYPOGLYCEMIC AGENTS
|
NSAIDS CONCURRENT ADMINISTRATION MAY DECREASE THE ANTIHYPERTENSIVE EFFECT OF THE DRUG
|
ANTICOAGULANT EFFECT IS INCREASED OF ORAL ANTICOAGULANTS
|
WHILE STUDIES HAVE NOT SHOWN INTERACTIONS WITH ORAL ANTICOAGULANTS, CONCURRENT THERAPY REQUIRES CLOSE MONITORING OF PATIENTS FOR POTENTIAL MODIFICATION IN ANTICOAGULANTS DOSAGE
|
CO-ADMINISTRATION OF NON-STEROIDAL ANTI-INFLAMMATORY WITH ASPIRIN MAY INCREASE BLEEDING OR LEAD TO DECREASED RENAL FUNCTION
|
KETOROLAC ASSOCIATED BLEEDING RISK IS INCREASED BY OTHER NSAIDS, ASPIRIN & BY PENTOXIPHYLLINE
|
CONCURRENT ADMINISTRATION MAY LEAD TO INCREASED G.I. SIDE EFFECTS
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE INCIDENCE OF G.I. SIDE EFFECTS AND RENAL SIDE EFFECTS
|
KETOROLAC ASSOCIATED BLEEDING RISK IS INCREASED BY OTHER NSAIDS, ASPIRIN & BY PENTOXIPHYLLINE
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE INCIDENCE OF G.I. SIDE EFFECTS
|
CONCURRENT ADMINISTRATION MAY LEAD TO INCREASED G.I. SIDE EFFECTS
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE INCIDENCE OF G.I. SIDE EFFECTS
|
CONCURRENT ADMINISTRATION MAY LEAD TO INCREASED G.I. SIDE EFFECTS
|
KETOROLAC ASSOCIATED BLEEDING RISK IS INCREASED BY OTHER NSAIDS, ASPIRIN & BY PENTOXIPHYLLINE
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE INCIDENCE OF G.I. SIDE EFFECTS
|
CO-ADMINISTRATION WITH NSAIDS HAS RESULTED IN INCREASED BUN, SERUM CREATININE AND SERUM POTASSIUM LEVELS, AND WEIGHT GAIN
|
BOTH HYPO AND HYPERGLYCEMIC EFFECTS HAVE BEEN REPORTED RARELY ; POSSIBILITY EXISTS THAT DICLOFENAC MAY ALTER PATIENTS RESPONSE TO ORAL HYPOGLYCEMIC AGENTS
|
BOTH HYPO AND HYPERGLYCEMIC EFFECTS HAVE BEEN REPORTED RARELY ; POSSIBILITY EXISTS THAT DICLOFENAC MAY ALTER PATIENTS RESPONSE TO ORAL HYPOGLYCEMIC AGENTS
|
CO-ADMINISTRATION OF NON-STEROIDAL ANTI-INFLAMMATORY WITH ASPIRIN MAY INCREASE BLEEDING OR LEAD TO DECREASED RENAL FUNCTION
|
KETOROLAC ASSOCIATED BLEEDING RISK IS INCREASED BY OTHER NSAIDS, ASPIRIN & BY PENTOXIPHYLLINE
|
CONCURRENT ADMINISTRATION MAY LEAD TO INCREASED G.I. SIDE EFFECTS
|
NSAIDS MAY CAUSE SEVERE DROWSINESS & CONFUSION WHEN CONCURRENTLY ADMINISTERED
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE RISK OF HAEMORRHAGE
|
BOTH HYPO AND HYPERGLYCEMIC EFFECTS HAVE BEEN REPORTED RARELY ; POSSIBILITY EXISTS THAT DICLOFENAC MAY ALTER PATIENTS RESPONSE TO ORAL HYPOGLYCEMIC AGENTS
|
BOTH HYPO AND HYPERGLYCEMIC EFFECTS HAVE BEEN REPORTED RARELY ; POSSIBILITY EXISTS THAT DICLOFENAC MAY ALTER PATIENTS RESPONSE TO ORAL HYPOGLYCEMIC AGENTS
|
BOTH HYPO AND HYPERGLYCEMIC EFFECTS HAVE BEEN REPORTED RARELY ; POSSIBILITY EXISTS THAT DICLOFENAC MAY ALTER PATIENTS RESPONSE TO ORAL HYPOGLYCEMIC AGENTS
|
BOTH HYPO AND HYPERGLYCEMIC EFFECTS HAVE BEEN REPORTED RARELY ; POSSIBILITY EXISTS THAT DICLOFENAC MAY ALTER PATIENTS RESPONSE TO ORAL HYPOGLYCEMIC AGENTS
|
BOTH HYPO AND HYPERGLYCEMIC EFFECTS HAVE BEEN REPORTED RARELY ; POSSIBILITY EXISTS THAT DICLOFENAC MAY ALTER PATIENTS RESPONSE TO ORAL HYPOGLYCEMIC AGENTS
|
CONCURRENT ADMINISTRATION MAY LEAD TO INCREASED G.I. SIDE EFFECTS
|
CONCURRENT ADMINISTRATION MAY LEAD TO INCREASED G.I. SIDE EFFECTS
|
BOTH HYPO AND HYPERGLYCEMIC EFFECTS HAVE BEEN REPORTED RARELY ; POSSIBILITY EXISTS THAT DICLOFENAC MAY ALTER PATIENTS RESPONSE TO ORAL HYPOGLYCEMIC AGENTS
|
BOTH HYPO AND HYPERGLYCEMIC EFFECTS HAVE BEEN REPORTED RARELY ; POSSIBILITY EXISTS THAT DICLOFENAC MAY ALTER PATIENTS RESPONSE TO ORAL HYPOGLYCEMIC AGENTS
|
NSAIDS CONCURRENT ADMINISTRATION MAY DECREASE THE ANTIHYPERTENSIVE EFFECT OF THE DRUG
|
BOTH HYPO AND HYPERGLYCEMIC EFFECTS HAVE BEEN REPORTED RARELY ; POSSIBILITY EXISTS THAT DICLOFENAC MAY ALTER PATIENTS RESPONSE TO ORAL HYPOGLYCEMIC AGENTS
|
BOTH HYPO AND HYPERGLYCEMIC EFFECTS HAVE BEEN REPORTED RARELY ; POSSIBILITY EXISTS THAT DICLOFENAC MAY ALTER PATIENTS RESPONSE TO ORAL HYPOGLYCEMIC AGENTS
|
BOTH HYPO AND HYPERGLYCEMIC EFFECTS HAVE BEEN REPORTED RARELY ; POSSIBILITY EXISTS THAT DICLOFENAC MAY ALTER PATIENTS RESPONSE TO ORAL HYPOGLYCEMIC AGENTS
|
NSAIDS IN SOME PATIENTS CAN REDUCE THE DIURETIC, NATRIURETIC & ANTIHYPERTENSIVE EFFECTS OF LOOP, POTASSIUM SPARING OR THIAZIDE DIURETICS
|
NSAIDS CONCURRENT ADMINISTRATION MAY POSE INCREASED RISK OF HYPERKALEMIA & NEPHROTOXICITY
|
CO-ADMINISTRATION IN PATIENTS WITH COMPROMISED RENAL FUNCTION WHO ARE BEING TREATED WITH NSAIDS MAY RESULT IN A FURTHER DETERIORATION OF RENAL FUNCTION
|
NSAIDS CONCURRENT ADMINISTRATION MAY DECREASE THE ANTIHYPERTENSIVE EFFECT OF THE DRUG
|
KETOROLAC ASSOCIATED BLEEDING RISK IS INCREASED BY OTHER NSAIDS, ASPIRIN & BY PENTOXIPHYLLINE
|
NSAIDS CONCURRENT ADMINISTRATION MAY DECREASE THE ANTIHYPERTENSIVE EFFECT OF THE DRUG
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
BOTH HYPO AND HYPERGLYCEMIC EFFECTS HAVE BEEN REPORTED RARELY ; POSSIBILITY EXISTS THAT DICLOFENAC MAY ALTER PATIENTS RESPONSE TO ORAL HYPOGLYCEMIC AGENTS
|
NSAIDS IN SOME PATIENTS CAN REDUCE THE DIURETIC, NATRIURETIC & ANTIHYPERTENSIVE EFFECTS OF LOOP, POTASSIUM SPARING OR THIAZIDE DIURETICS
|
CO-ADMINISTRATION OF NON-STEROIDAL ANTI-INFLAMMATORY WITH ASPIRIN MAY INCREASE BLEEDING OR LEAD TO DECREASED RENAL FUNCTION
|
KETOROLAC ASSOCIATED BLEEDING RISK IS INCREASED BY OTHER NSAIDS, ASPIRIN & BY PENTOXIPHYLLINE
|
CNS EXCITATION MAY OCCUR WITH CONCURRENT ADMINISTRATION; MAY CAUSE CONVULSIONS
|
CNS EXCITATION MAY OCCUR WITH CONCURRENT ADMINISTRATION; MAY CAUSE CONVULSIONS
|
CONCURRENT ADMINISTRATION MAY LEAD TO INCREASED G.I. SIDE EFFECTS
|
CONCURRENT ADMINISTRATION MAY LEAD TO INCREASED G.I. SIDE EFFECTS
|
NSAIDS IN SOME PATIENTS CAN REDUCE THE DIURETIC, NATRIURETIC & ANTIHYPERTENSIVE EFFECTS OF LOOP, POTASSIUM SPARING OR THIAZIDE DIURETICS
|
NSAIDS CONCURRENT ADMINISTRATION MAY DECREASE THE ANTIHYPERTENSIVE EFFECT OF THE DRUG
|
KETOROLAC ASSOCIATED BLEEDING RISK IS INCREASED BY OTHER NSAIDS, ASPIRIN & BY PENTOXIPHYLLINE
|
CNS EXCITATION MAY OCCUR WITH CONCURRENT ADMINISTRATION; MAY CAUSE CONVULSIONS
|
CO-ADMINISTRATION OF NSAIDS WITH ACE INHIBITORS MAY RESULT IN DIMINISHED ANTIHYPERTENSIVE EFFECT OF ACE INHIBITORS
|
DICLOFENAC CAN INHIBIT THE ACTIVITY OF DIURETICS ; CONCOMITANT TREATMENT MAY BE ASSOCIATED WITH HYPERKALEMIA
|
NSAIDS CONCURRENT ADMINISTRATION MAY POSE INCREASED RISK OF HYPERKALEMIA & NEPHROTOXICITY
|
KETOROLAC ASSOCIATED BLEEDING RISK IS INCREASED BY OTHER NSAIDS, ASPIRIN & BY PENTOXIPHYLLINE
|
CO-ADMINISTRATION OF NON-STEROIDAL ANTI-INFLAMMATORY WITH ASPIRIN MAY INCREASE BLEEDING OR LEAD TO DECREASED RENAL FUNCTION
|
KETOROLAC ASSOCIATED BLEEDING RISK IS INCREASED BY OTHER NSAIDS, ASPIRIN & BY PENTOXIPHYLLINE
|
CO-ADMINISTRATION MAY INTERFERE WITH THE BENEFITS OF ASPIRIN TAKEN FOR HEART DISEASE, SHOULD BE TAKEN ON DIFFERENT TIMES
|
NSAIDS CONCURRENT ADMINISTRATION MAY DECREASE THE ANTIHYPERTENSIVE EFFECT OF THE DRUG
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE INCIDENCE OF G.I. SIDE EFFECTS
|
NSAIDS CONCURRENT ADMINISTRATION MAY DECREASE THE ANTIHYPERTENSIVE EFFECT OF THE DRUG
|
CO-ADMINISTRATION IN PATIENTS WITH COMPROMISED RENAL FUNCTION WHO ARE BEING TREATED WITH NSAIDS MAY RESULT IN A FURTHER DETERIORATION OF RENAL FUNCTION
|
NSAIDS IN SOME PATIENTS CAN REDUCE THE DIURETIC, NATRIURETIC & ANTIHYPERTENSIVE EFFECTS OF LOOP, POTASSIUM SPARING OR THIAZIDE DIURETICS
|
KETOROLAC ASSOCIATED BLEEDING RISK IS INCREASED BY OTHER NSAIDS, ASPIRIN & BY PENTOXIPHYLLINE
|
CONCURRENT ADMINISTRATION MAY LEAD TO INCREASED G.I. SIDE EFFECTS
|
NSAIDS CONCURRENT ADMINISTRATION MAY DECREASE THE ANTIHYPERTENSIVE EFFECT OF THE DRUG
|
CNS EXCITATION MAY OCCUR WITH CONCURRENT ADMINISTRATION; MAY CAUSE CONVULSIONS
|
NSAIDS CONCURRENT ADMINISTRATION MAY DECREASE THE ANTIHYPERTENSIVE EFFECT OF THE DRUG
|
CO-ADMINISTRATION IN PATIENTS WITH COMPROMISED RENAL FUNCTION WHO ARE BEING TREATED WITH NSAIDS MAY RESULT IN A FURTHER DETERIORATION OF RENAL FUNCTION
|
DECREASED LITHIUM RENAL CLEARANCE RESULTING IN INCREASED LITHIUM PLASMA LEVELS ; POTENTIAL FOR LITHIUM TOXICITY
|
CNS EXCITATION MAY OCCUR WITH CONCURRENT ADMINISTRATION; MAY CAUSE CONVULSIONS
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE RISK OF HAEMORRHAGE
|
CO-ADMINISTRATION OF NON-STEROIDAL ANTI-INFLAMMATORY WITH ASPIRIN MAY INCREASE BLEEDING OR LEAD TO DECREASED RENAL FUNCTION
|
KETOROLAC ASSOCIATED BLEEDING RISK IS INCREASED BY OTHER NSAIDS, ASPIRIN & BY PENTOXIPHYLLINE
|
KETOROLAC ASSOCIATED BLEEDING RISK IS INCREASED BY OTHER NSAIDS, ASPIRIN & BY PENTOXIPHYLLINE
|
KETOROLAC ASSOCIATED BLEEDING RISK IS INCREASED BY OTHER NSAIDS, ASPIRIN & BY PENTOXIPHYLLINE
|
KETOROLAC ASSOCIATED BLEEDING RISK IS INCREASED BY OTHER NSAIDS, ASPIRIN & BY PENTOXIPHYLLINE
|
BOTH HYPO AND HYPERGLYCEMIC EFFECTS HAVE BEEN REPORTED RARELY ; POSSIBILITY EXISTS THAT DICLOFENAC MAY ALTER PATIENTS RESPONSE TO ORAL HYPOGLYCEMIC AGENTS
|
CO-ADMINISTRATION MAY INCREASE SERUM METHOTREXATE CONCENTRATIONS RESULTING IN METHOTREXATE TOXICITY SINCE NSAIDS MAY AFFECT RENAL PROSTAGLANDINS
|
CO-ADMINISTRATION OF NSAIDS ELEVATE AND PROLONG SERUM METHOTREXATE CONCENTRATIONS RESULTING IN DEATHS FROM SEVERE HEMATOLOGIC AND GASTROINTESTINAL TOXICITY; CONCURRENT AND/OR SEQUENTIAL USE OF NSAIDS WITH HIGH DOSE METHOTREXATE SHOULD BE AVOIDED
|
CO-ADMINISTRATION OF NON-STEROIDAL ANTI-INFLAMMATORY WITH ASPIRIN MAY INCREASE BLEEDING OR LEAD TO DECREASED RENAL FUNCTION
|
BOTH HYPO AND HYPERGLYCEMIC EFFECTS HAVE BEEN REPORTED RARELY ; POSSIBILITY EXISTS THAT DICLOFENAC MAY ALTER PATIENTS RESPONSE TO ORAL HYPOGLYCEMIC AGENTS
|
NSAIDS INHIBIT SPREADING ACTION
|
CO-ADMINISTRATION OF THIAZIDE DIURETICS AND NSAIDS AGENTS CAN REDUCE THE DIURETIC, NATIURETIC, AND ANTIHYPERTENSIVE EFFECTS
|
CONCURRENT ADMINISTRATION MAY LEAD TO INCREASED G.I. SIDE EFFECTS
|
CONCURRENT ADMINISTRATION MAY LEAD TO INCREASED G.I. SIDE EFFECTS
|
CONCURRENT ADMINISTRATION MAY LEAD TO INCREASED G.I. SIDE EFFECTS
|
CONCURRENT ADMINISTRATION MAY LEAD TO INCREASED G.I. SIDE EFFECTS
|
CONCURRENT ADMINISTRATION MAY LEAD TO INCREASED G.I. SIDE EFFECTS
|
NSAIDS IN SOME PATIENTS CAN REDUCE THE DIURETIC, NATRIURETIC & ANTIHYPERTENSIVE EFFECTS OF LOOP, POTASSIUM SPARING OR THIAZIDE DIURETICS
|
KETOROLAC ASSOCIATED BLEEDING RISK IS INCREASED BY OTHER NSAIDS, ASPIRIN & BY PENTOXIPHYLLINE
|
CO-ADMINISTRATION OF THIAZIDE DIURETICS AND NSAIDS AGENTS CAN REDUCE THE DIURETIC, NATIURETIC, AND ANTIHYPERTENSIVE EFFECTS
|
KETOROLAC ASSOCIATED BLEEDING RISK IS INCREASED BY OTHER NSAIDS, ASPIRIN & BY PENTOXIPHYLLINE
|
BOTH HYPO AND HYPERGLYCEMIC EFFECTS HAVE BEEN REPORTED RARELY ; POSSIBILITY EXISTS THAT DICLOFENAC MAY ALTER PATIENTS RESPONSE TO ORAL HYPOGLYCEMIC AGENTS
|
BOTH HYPO AND HYPERGLYCEMIC EFFECTS HAVE BEEN REPORTED RARELY ; POSSIBILITY EXISTS THAT DICLOFENAC MAY ALTER PATIENTS RESPONSE TO ORAL HYPOGLYCEMIC AGENTS
|
CONCURRENT ADMINISTRATION MAY LEAD TO INCREASED G.I. SIDE EFFECTS
|